Diabetes Technology in People with Type 2 Diabetes: Novel Indications
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Against this backdrop, digital health technology (DHT) has the potential to address the aforementioned care gaps in people with EOT2D [9–12].”
From Digital Management of Early-Onset Type 2 Diabetes: Empowerment, Challenges, and Future Outlook (2026) · cites this paper as [10]
In the citing paper
“By integrating sensing technology, mobile computing, data analytics, and remote communication. DHT enables continuous disease state monitoring, real-time behavioral interventions, and efficient patient-provider communication [9–12].”
From Digital Management of Early-Onset Type 2 Diabetes: Empowerment, Challenges, and Future Outlook (2026) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ismail-Beigi, F., Craven, T., Banerji, M. A., Basile, J., Calles, J., Cohen, R. M., Cuddihy, R., Cushman, W. C., Genuth, S., Grimm, R. H., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60576-4 · Cited by 1,428
Trends in diabetes treatment and control in U.S. adults, 1999-2018
Fang, M., Wang, D., Coresh, J., & Selvin, E. (2021) · New England Journal of Medicine · doi:10.1056/nejmsa2032271 · Cited by 690 · cited 1×
“Despite several developments in pharmacotherapy, a recent national report in the United States showed that the prevalence of glycemic control, defined as HbA1c 7%, decreased from 57 to 50%, instead of improving [7].”
Beck, R. W., Riddlesworth, T. D., Ruedy, K., Ahmann, A., Haller, S., Kruger, D., McGill, J. B., Polonsky, W., Price, D., Aronoff, S., et al. (2017) · Annals of Internal Medicine · doi:10.7326/m16-2855 · Cited by 635 · cited 1×
“The use of rtCGM improved HbA1c by 1.0% from baseline over 12 weeks (adjusted difference in mean change in HbA1c level between groups, − 0.3% [95% CI, − 0.6 to − 0.1%]; P = 0.005) [26].”
InfluentialHaak, T., Hanaire, H., Ajjan, R., Hermanns, N., Riveline, J.-P., & Rayman, G. (2017) · Diabetes Therapy · doi:10.1007/s13300-016-0223-6 · Cited by 623 · cited 1×
“…mean glucose, standard deviation of glucose, mean amplitude of glycemic excursions) in non-insulin-treated T2D [23], T2D treated with basal insulin only [24], and in a randomized controlled, open-label trial of people with T2D treated with multiple daily injection (MDI) insulin therapy [25].”
Martens, T., Beck, R. W., Bailey, R., Ruedy, K. J., Calhoun, P., Peters, A. L., Pop-Busui, R., Philis-Tsimikas, A., Bao, S., Umpierrez, G., et al. (2021) · JAMA · doi:10.1001/jama.2021.7444 · Cited by 543
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Self-citationPhillip, M., Nimri, R., Bergenstal, R. M., Barnard-Kelly, K., Danne, T., Hovorka, R., Kovatchev, B. P., Messer, L. H., Parkin, C. G., Ambler-Osborn, L., et al. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnac022 · Cited by 443
Samson, S. L., Vellanki, P., Blonde, L., Christofides, E. A., Galindo, R. J., Hirsch, I. B., Isaacs, S. D., Izuora, K. E., Low Wang, C. C., Twining, C. L., et al. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.02.001 · Cited by 375
Self-citation7. Diabetes Technology: Standards of Care in Diabetes — 2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s007 · Cited by 301
Grunberger, G., Sherr, J., Allende, M., Blevins, T., Bode, B., Handelsman, Y., Hellman, R., Lajara, R., Roberts, V. L., Rodbard, D., et al. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.04.008 · Cited by 288
Reznik, Y., Cohen, O., Aronson, R., Conget, I., Runzis, S., Castaneda, J., & Lee, S. W. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61037-0 · Cited by 233
Yaron, M., Roitman, E., Aharon-Hananel, G., Landau, Z., Ganz, T., Yanuv, I., Rozenberg, A., Karp, M., Ish-Shalom, M., Singer, J., et al. (2019) · Diabetes Care · doi:10.2337/dc18-0166 · Cited by 211
Roussel, R., Riveline, J.-P., Vicaut, E., de Pouvourville, G., Detournay, B., Emery, C., Levrat-Guillen, F., & Guerci, B. (2021) · Diabetes Care · doi:10.2337/dc20-1690 · Cited by 173 · cited 1×
“In observational longitudinal studies, the use of isCGM in people with T2D reduces acute complications leading to hospitalization [22] (DKA, hypoglycemia, diabetic coma, and hyperglycemia).”
Heinemann, L., Schoemaker, M., Schmelzeisen-Redecker, G., Hinzmann, R., Kassab, A., Freckmann, G., Reiterer, F., & Del Re, L. (2020) · Journal of Diabetes Science and Technology · doi:10.1177/1932296819855670 · Cited by 170 · cited 3×
“The lesser the MARD, the closer the CGM values are to the comparison values [11].”
InfluentialWada, E., Onoue, T., Kobayashi, T., Handa, T., Hayase, A., Ito, M., Furukawa, M., Okuji, T., Okada, N., Iwama, S., et al. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-001115 · Cited by 157 · cited 1×
“It improves glycemic control (HbA1c, mean glucose, standard deviation of glucose, mean amplitude of glycemic excursions) in non-insulin-treated T2D [23], T2D treated with basal insulin only [24], and in a randomized controlled, open-label trial of people with T2D treated with multiple daily…”
Aronson, R., Brown, R. E., Chu, L., Bajaj, H. S., Khandwala, H., Abitbol, A., Malakieh, N., & Goldenberg, R. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14949 · Cited by 118
Forlenza, G. P., Carlson, A. L., Galindo, R. J., Kruger, D. F., Levy, C. J., McGill, J. B., Umpierrez, G., & Aleppo, G. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0206 · Cited by 70 · cited 1×
“A reduction in time spent in level 2 hypoglycemia and hyperglycemia was also noted [53].”
Self-citationDavis, G. M., Peters, A. L., Bode, B. W., Carlson, A. L., Dumais, B., Vienneau, T. E., Huyett, L. M., & Ly, T. T. (2023) · Diabetes Care · doi:10.2337/dc22-1915 · Cited by 69
MacLeod, J., Im, G. H., Smith, M., & Vigersky, R. A. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0365 · Cited by 44
Galindo, R. J., Ramos, C., Cardona, S., Vellanki, P., Davis, G. M., Oladejo, O., Albury, B., Dhruv, N., Peng, L., & Umpierrez, G. E. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968211033837 · Cited by 43 · cited 1×
“…of a smart insulin pen cap with insulin omission alerts attached to insulin pens resulted in lower mean daily blood glucose (147.0 ± 34 vs 157.6 ± 42 mg/dL, P 0.01), and greater reduction in HbA1c from baseline (− 0.98% vs − 0.72%, P = 0.006) when comparing active phase to the control phase [37].”
InfluentialSelf-citationGrunberger, G., Rosenfeld, C. R., Bode, B. W., Abbott, S. D., Nikkel, C., Shi, L., & Strange, P. (2020) · Drugs - Real World Outcomes · doi:10.1007/s40801-019-00173-8 · Cited by 19 · cited 1×
“Similarly, in two studies evaluating real-world effectiveness of the V-Go device, a total of 471 people with T2D were followed, and a reduction in HbA1c of 0.64 to 1.04% was noted with a reduction in total daily dose of insulin [44, 45].”
Influential936-P: three-month interim analysis from the prospective bigfoot unity real world study (BURST)
MALONE, J. K., BECK, R., TILLMAN, J., CALHOUN, P., MOUSE, T. J., BAILEY, R., OLSON, B. P., VAUGHAN, S., & NAUREEN SHEIKH, F. (2023) · Diabetes · doi:10.2337/db23-936-p · Cited by 2 · cited 1×
“An interim analysis of this study showed that 85% of participants enrolled had T2D and mean A1C decreased from 9.2 ± 1.8% at baseline to 7.9 ± 1.3% at 3 months (mean difference − 1.2%, 95% CI − 1.6 to − 0.8, P 0.001) [36].”
Influential
Research works printed but not linked: 21
- UK Prospective Diabetes Study (UKPDS). Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837–53. https://doi.org/10.1016/S0140-6736(98)07019-6. · DOI · Paper page
- Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129–39. https://doi.org/10.1056/NEJMoa0808431. · DOI · Paper page
- ADVANCE Collaborative Group, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes N Engl J Med 2008;358(24):2560–2572 https://doi.org/10.1056/NEJMoa0802987 · DOI · Paper page
- Galindo RJ, Trujillo JM, Low Wang CC, McCoy RG. Advances in the management of type 2 diabetes in adults. BMJ Med. 2023;2(1):e000372. https://doi.org/10.1136/bmjmed-2022-000372. · DOI
- Lingvay I, Agarwal S. A revolution in obesity treatment. Nat Med. 2023;29(10):2406–8. https://doi.org/10.1038/s41591-023-02538-7. · DOI
- • Galindo RJ, Aleppo G. Continuous glucose monitoring: the achievement of 100 years of innovation in diabetes technology Diabetes Res Clin Pract. 2020;170:108502. https://doi.org/10.1016/j.diabres.2020.108502. This article covers the salient advances in CGM technology over time and provides tips on implementation of CGM in the medical office. · DOI · Paper page
- Bergenstal RM, Ahmann AJ, Bailey T, et al. Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the ambulatory glucose profile. J Diabetes Sci Technol. 2013;7(2):562–78. https://doi.org/10.1177/193229681300700234. · DOI · Paper page
- Das SK, Nayak KK, Krishnaswamy PR, et al. Review—electrochemistry and other emerging technologies for continuous glucose monitoring devices. ECS Sensors Plus. 2022;1(3) https://doi.org/10.1149/2754-2726/ac7abb · DOI
- Puhr S, Derdzinski M, Welsh JB, Parker AS, Walker T, Price DA. Real-world hypoglycemia avoidance with a continuous glucose monitoring system’s predictive low glucose alert. Diabetes Technol Ther. 2019;21(4):155–8. https://doi.org/10.1089/dia.2018.0359. · DOI · Paper page
- Reiterer F, Polterauer P, Schoemaker M, et al. Significance and reliability of MARD for the accuracy of CGM systems. J Diabetes Sci Technol. 2017;11(1):59–67. https://doi.org/10.1177/1932296816662047. · DOI · Paper page
- Elliott T, Beca S, Beharry R, Tsoukas MA, Zarruk A, Abitbol A. The impact of flash glucose monitoring on glycated hemoglobin in type 2 diabetes managed with basal insulin in Canada: a retrospective real-world chart review study. Diab Vasc Dis Res. 2021;18(4):14791641211021374. https://doi.org/10.1177/14791641211021374. · DOI · Paper page
- Ehrhardt N, Al ZE. Continuous glucose monitoring as a behavior modification tool. Clin Diabetes. 2020;38(2):126–31. https://doi.org/10.2337/cd19-0037. · DOI · Paper page
- Ananthanarayanan V, Mithun Haridas TP, Naveen R, et al. Reliable and affordable embedded system solution for continuous blood glucose maintaining system with wireless connectivity to blood glucose measuring system. IJCA Proceedings on Amrita International Conference of Women in Computing. 2013; AICWIC(2):36–43
- Boughton CK, Hovorka R. Automated insulin delivery in adults. Endocrinol Metab Clin North Am. 2020;49(1):167–78. https://doi.org/10.1016/j.ecl.2019.10.007. · DOI
- Cziraky MJ, Abbott S, Nguyen M, et al. A pragmatic clinical trial to compare the real-world effectiveness of V-Go versus standard delivery of insulin in patients with advanced type 2 diabetes. J Health Econ Outcomes Res. 2019 6(2):70–83. https://doi.org/10.36469/9731 · DOI
- Hundal R, Kowalyk S, Wakim A, Nikkel C, Sink Ii JH, Doyle M Multicenter real-world assessment of the effectiveness of V-Go wearable insulin delivery device in adult patients with type 2 diabetes (ENABLE Study): a retrospective analysis. Med Devices (Auckl). 2020;13:283–291 https://doi.org/10.2147/MDER.S265869 · DOI
- Bergenstal RM, Peyrot M, Dreon DM, et al. Implementation of basal-bolus therapy in type 2 diabetes: a randomized controlled trial comparing bolus insulin delivery using an insulin patch with an insulin pen. Diabetes Technol Ther. 2019;21(5):273–85. https://doi.org/10.1089/dia.2018.0298. · DOI · Paper page
- Bergenstal RM, Johnson ML, Aroda VR, et al. Comparing patch vs pen bolus insulin delivery in type 2 diabetes using continuous glucose monitoring metrics and profiles. J Diabetes Sci Technol. 2022;16(5):1167–73. https://doi.org/10.1177/19322968211016513. · DOI
- Isaacs D, Kruger DF, Shoger E, Chawla H. Patient perceptions of satisfaction and quality of life regarding use of a novel insulin delivery device. Clin Diabetes. 2023;41(2):198–207. https://doi.org/10.2337/cd22-0034. · DOI
- Habif S, Constantin A, Mueller L, et al. 126-LB: glycemic outcomes for people with type 1 and type 2 diabetes using control-IQ technology: real-world data from early adopters. Diabetes. 2020, 69(Supplement_1): 126–LB https://doi.org/10.2337/db20-126-lb · DOI
- Peters AL, Ahmann AJ, Hirsch IB, Raymond JK. Advances in glucose monitoring and automated insulin delivery: supplement to Endocrine Society clinical practice guidelines. J Endocr Soc. 2018;2(11):1214–25. https://doi.org/10.1210/js.2018-00262. · DOI
Cited by
Digital Management of Early-Onset Type 2 Diabetes: Empowerment, Challenges, and Future Outlook
Guo, L.-J., Low, K.-S., Tae, S.-K., & Lim, L.-L. (2026) · Current Diabetes Reports · doi:10.1007/s11892-026-01633-6
Metadata
- Authors
- Agarwal, S., Galindo, R. J., Shah, A. V., & Abreu, M.
- Venue
- Current Diabetes Reports
- Published
- 2024-02-29
- Volume
- 24
- Issue
- 5
- Pages
- 85-95
- ISSN
- 1534-4827
- 1539-0829
- Cited by
- 12
- References
- 22
- Language
- en
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.